首页> 外文期刊>Transplant international : >No evidence of occult hepatitis C virus (HCV) infection in serum of HCV antibody-positive HCV RNA-negative kidney-transplant patients.
【24h】

No evidence of occult hepatitis C virus (HCV) infection in serum of HCV antibody-positive HCV RNA-negative kidney-transplant patients.

机译:在HCV抗体阳性,HCV RNA阴性的肾脏移植患者的血清中没有隐匿性丙型肝炎病毒(HCV)感染的证据。

获取原文
获取原文并翻译 | 示例
           

摘要

Persistence of hepatitis C virus (HCV) in patients who cleared HCV is still debated. Occult HCV infection is described as the presence of detectable HCV RNA in liver or peripheral blood mononuclear cells (PBMCs) of patients with undetectable plasma HCV-RNA by conventional PCR assays. We have assessed the persistence of HCV in 26 kidney-transplant patients, followed up for 10.5 years (range 2-16), after HCV elimination while on hemodialysis. If HCV really did persist, arising out of the loss of immune control caused by institution of the regimen of immunosuppressive drugs after kidney transplantation, HCV reactivation would have taken place. Their immunosuppression relied on calcineurin inhibitors (100%), and/or steroids (62%), and/or antimetabolites (94%). An induction therapy, given to 22 patients, relied on rabbit antithymocyte globulin (59%) or anti-IL2-receptor blockers (32%). All patients had undetectable HCV RNA as ascertained by several conventional tests. At the last follow-up, no residual HCV RNA was detected in the five liver biopsies, the 26 plasma, and in the 37 nonstimulated and 24 stimulated PBMCs tested with an ultrasensitive RT-PCR assay (detection limit, 2 IU/ml). No biochemical or virologic relapse was seen during follow-up. The absence of HCV relapse in formerly HCV-infected immunocompromised patients suggests the complete eradication of HCV after its elimination while on dialysis.
机译:丙型肝炎病毒(HCV)在清除HCV的患者中的持久性仍存在争议。隐匿性HCV感染被描述为通过常规PCR分析在血浆HCV-RNA不可检测的患者的肝或外周血单核细胞(PBMC)中存在可检测的HCV RNA。我们评估了26例肾移植患者的HCV持续性,并在进行血液透析HCV消除后随访了10.5年(范围2-16)。如果HCV确实持续存在,是由于肾移植后因实施免疫抑制药物而导致免疫控制丧失,则HCV会重新活化。它们的免疫抑制依赖于钙调神经磷酸酶抑制剂(100%)和/或类固醇(62%)和/或抗代谢物(94%)。对22位患者进行的诱导疗法依赖于兔抗胸腺细胞球蛋白(59%)或抗IL2受体阻滞剂(32%)。所有患者均具有通过常规检测确定的无法检测到的HCV RNA。在最后一次随访中,在5例肝活检,26血浆,以及37例未经刺激和24例经超敏RT-PCR检测的PBMC中未检测到残留的HCV RNA(检测限为2 IU / ml)。随访期间未见生化或病毒学复发。以前被HCV感染的免疫功能低下的患者中HCV没有复发提示透析后消除HCV后可以完全根除。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号